• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Eyes and Vision
    • Heart and Circulation
    • Infections
    • Mental Health
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Heart and Circulation

Mar 16 2022

How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary

A new plain language summary of publication published in Future Cardiology summarises some of the results of a study called ATTR-ACT. The article looked at the participants of the study who took placebo to learn how transthyretin amyloid cardiomyopathy progressed without treatment.

Read the article in full here.

Click here  to read the original article on which this summary is based.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Heart and Circulation · Tagged: Amyloidosis, cardiomyopathy, heart failure, natural history, tafamidis, transthyretin amyloid cardiomyopathy

Mar 04 2022

Is the sodium in sodium oxybate a risk for heart health? A plain language summary of publication

The latest plain language summary published in Future Cardiology summarizes an article originally published in Sleep Medicine. The article looks at the levels of sodium in sodium oxybate, a medication for people with narcolepsy, and whether there is any risk of cardiovascular problems as a result of taking the treatment.

Read the full article here.

The original article on which this summary is based is called ‘The sodium in sodium oxybate: is there cause for concern?’ and was originally published in the journal Sleep Medicine. The original article can be read here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Heart and Circulation · Tagged: cardiovascular, narcolepsy, safety, salt, sodium oxybate

Nov 15 2021

Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary

This plain language summary describes the results of a study called ATTR-ACT, which was published in the American Journal of Cardiology. In ATTR-ACT, researchers looked at the effects of tafamidis treatment in people with transthyretin amyloid cardiomyopathy. This summary is intended to help people with ATTR-CM and caregivers understand the disease, its treatment, and results
from ATTR-ACT.

Read the full article here.

The original article, called ‘Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)’ was published in the American Journal of Cardiology and can be read here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

 

Written by Joanne Walker · Categorized: Heart and Circulation · Tagged: Amyloidosis, cardiomyopathy, heart failure, quality of life, tafamidis, transthyretin

May 21 2021

A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy

The EXPLORER-HCM trial, originally published in The Lancet, looked at the role of mavacamten as a potential treatment for hypertrophic cardiomyopathy. Wanting to help patients and other non-specialists understand this study, the authors have developed a plain language summary of the publication.

Written by Cynthia Burstein Waldman (a patient author) and Anjali Owens, this new article called ‘A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy’ has been published in Future Cardiology.

Read the article in full here.

The original article, entitled ‘Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial’, published in The Lancet, can be found here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Heart and Circulation · Tagged: clinical trial, EXPLORER HCM, hypertrophic cardiomyopathy, mavacamten, myosin

Copyright © 2022 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·